For example, the facts that CD36 inhibition reduces EMT in breast cancer (Gyamfi et al., 2021), HCC (Nath et al., 2015), and cervical cancer (Deng et al., 2019), and drastically affects metastasis with a modest/null effect in primary xenotransplants (Pascual et al., 2017) suggest that either the CD36-mediated metabolic switch is particularly important in the metastatic niche and/or CD36 plays a differential role in metastasis-initiating and tumor-initiating cells. This evidence concerns the gene CD36 and neoplasm.